Ratios of miRNAs in Peritoneal Exosomes are Useful Biomarkers to Predict Tumor Response to Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Gastric Cancer-Reference-Cited by-同舟云学术

Ratios of miRNAs in Peritoneal Exosomes are Useful Biomarkers to Predict Tumor Response to Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Gastric Cancer

Published:2020-08-17 Issue:13 Volume:27 Page:5057-5064
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Ohzawa Hideyuki,Kimura Yuki,Saito Akira,Yamaguchi Hironori,Miyato Hideyo,Sakuma Yasunaru,Horie Hisanaga,Hosoya Yoshinori,Lefor Alan Kawarai,Sata Naohiro,Kitayama Joji^ORCID

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-020-09007-2.pdf

Reference47 articles.

1. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.

2. Anter AH, Abdel-Latif RM. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Med. Oncol. 2013;30(1):451.

3. Guo X, Zhao F, Ma X, et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC cancer. 2019;19(1):1125.